

Lyon, February 24th, 2026

A-Alpha Bio and Edelris Collaborate on Molecular Glue Small Molecule Discovery Screening

A-Alpha Bio and Edelris are collaborating on a small-molecule screening effort, with Edelris applying its affinity selection–mass spectrometry (AS–MS) expertise to support A-Alpha Bio’s molecular glue discovery programs. The work targets novel basal protein–protein interactions identified by A-Alpha Bio, with an emphasis on identifying small molecules that bind to and stabilize these interfaces in ways that may enable molecular glue–like behavior and downstream functional modulation such as targeted degradation. Edelris is utilizing the EDEN (Edelris Discovery Engine) platform, conducting label–free affinity selection screening using its proprietary 2–million–compound Keymical Space library, characterized by structurally diverse, sp^3 –rich, natural product–inspired chemical matter, well suited for exploring difficult-to-drug protein–protein interaction surfaces.

“Combining A-Alpha Bio’s deep biological insights with our Keymical Space and the screening power of our AS-MS platform creates a uniquely potent discovery engine”, said Joseph Zolnerciks, Ph.D., Chief Business Officer at Edelris. “This synergy allows us to efficiently explore complex protein surfaces and interfaces using our diverse, three-dimensional chemical matter, significantly accelerating the path to clinical candidates.”